| 前收盘价格 | 309.69 |
| 收盘价格 | 313.00 |
| 成交量 | 448,937 |
| 平均成交量 (3个月) | 375,508 |
| 市值 | 38,826,393,600 |
| 预期市盈率 (P/E Forward) | 126.58 |
| 价格/销量 (P/S) | 7.68 |
| 股市价格/股市净资产 (P/B) | 10.12 |
| 52周波幅 | |
| 利润日期 | 6 Aug 2025 |
| 营业毛利率 | -9.40% |
| 营业利益率 (TTM) | 0.99% |
| 稀释每股收益 (EPS TTM) | -3.69 |
| 季度收入增长率 (YOY) | 48.60% |
| 总债务/股东权益 (D/E MRQ) | 28.49% |
| 流动比率 (MRQ) | 1.96 |
| 营业现金流 (OCF TTM) | 212.02 M |
| 杠杆自由现金流 (LFCF TTM) | -120.68 M |
| 资产报酬率 (ROA TTM) | -3.22% |
| 股东权益报酬率 (ROE TTM) | -11.44% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | BeOne Medicines Ltd. | 看涨 | - |
AIStockmoo 评分
0.0
| 分析师共识 | 3.0 |
| 内部交易活动 | -4.0 |
| 价格波动 | -3.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.00 |
|
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene’s revenue. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Mid Core |
| 内部持股比例 | 17.31% |
| 机构持股比例 | 43.94% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Baker Bros. Advisors Lp | 30 Jun 2025 | 8,799,053 |
| Hhlr Advisors, Ltd. | 30 Jun 2025 | 1,034,306 |
| Siren, L.L.C. | 30 Jun 2025 | 509,990 |
| Boxer Capital, Llc | 30 Sep 2024 | 500,000 |
| Paradigm Biocapital Advisors Lp | 30 Jun 2025 | 347,787 |
| Capital International, Inc./Ca/ | 30 Jun 2025 | 345,559 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 365.00 (Guggenheim, 13.58%) | 购买 |
| 中 | 354.50 (10.31%) | |
| 低 | 330.00 (Morgan Stanley, 2.69%) | 购买 |
| 平均值 | 351.00 (9.22%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 282.03 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Guggenheim | 07 Aug 2025 | 365.00 (13.58%) | 购买 | 298.29 |
| RBC Capital | 07 Aug 2025 | 364.00 (13.27%) | 购买 | 298.29 |
| 16 Jul 2025 | 349.00 (8.60%) | 购买 | 279.16 | |
| JP Morgan | 17 Jul 2025 | 345.00 (7.36%) | 购买 | 290.35 |
| 27 Jun 2025 | 321.00 (-0.11%) | 购买 | 241.20 | |
| Morgan Stanley | 27 Jun 2025 | 330.00 (2.69%) | 购买 | 241.20 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| LEE CHAN HENRY | - | 307.51 | -11,013 | -3,386,608 |
| WU XIAOBIN | - | 308.60 | -89,794 | -27,699,613 |
| 累积净数量 | -100,807 | |||
| 累积净值 ($) | -31,086,221 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 308.24 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| WU XIAOBIN | 职员 | 14 Aug 2025 | 自动卖出 (-) | 39,936 | 309.69 | 12,367,780 |
| WU XIAOBIN | 职员 | 14 Aug 2025 | 执行期权 | 39,936 | - | - |
| LEE CHAN HENRY | 职员 | 13 Aug 2025 | 自动卖出 (-) | 11,013 | 307.51 | 3,386,608 |
| LEE CHAN HENRY | 职员 | 13 Aug 2025 | 执行期权 | 8,230 | - | - |
| WU XIAOBIN | 职员 | 13 Aug 2025 | 自动卖出 (-) | 49,858 | 307.51 | 15,331,834 |
| WU XIAOBIN | 职员 | 13 Aug 2025 | 执行期权 | 49,858 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合